Ribocure Pharmaceuticals
Manufacturing · Nebraska, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8a Medicinaregatan 90, Gothenburg, Nebra...Website
www.ribocure.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Ribocure Pharmaceuticals
Ribocure Pharmaceuticals AB is a Swedish biotech company focused on the development of innovative RNA therapeutics, particularly targeting unmet medical needs in rare diseases related to cardiovascular, renal, and oncology areas. The company operates a specialized unit for Phase 2 clinical trials, known as the Ribocure Clinic, which is equipped with advanced research and imaging capabilities. Ribocure aims to establish itself as a leader in RNA research and development, leveraging its partnership with Ribo Life Science Co., Ltd. to enhance its oligonucleotide research platform. The company is actively seeking collaborations with academic institutions and enterprises to further its mission of creating groundbreaking treatments for patients worldwide.Explore more
Ribocure Pharmaceuticals Org Chart
SU
Director Clinical Pharmacometrics
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ribocure Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Ribocure Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Ribocure Pharmaceuticals
Check out if Ribocure Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Ribocure Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Ribocure Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Ribocure Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Ribocure Pharmaceuticals launches new products
Click to see if Ribocure Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Ribocure Pharmaceuticals as Masked Content
Find 3 more new buyers
Compare Similar Companies to Ribocure Pharmaceuticals
Compare insights from companies similar to Ribocure Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Ribocure Pharmaceuticals
<$5M
11-50
Private
-
2022
CN
Catarina NilssonSenior Director Clinical Pharmacology
Company Profile Activity
Activity Insights
Ribocure Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ribocure Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ribocure Pharmaceuticals.
Ribocure Pharmaceuticals Tech Stack
A closer look at the technologies used by Ribocure Pharmaceuticals
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Open Position
Ribocure Pharmaceuticals News & Media
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the...Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal...Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus...Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ribocure Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Ribocure Pharmaceuticals AB is a Swedish biotech company focused on the development of innovative RNA therapeutics, particularly targeting unmet medical needs in rare diseases related to cardiovascular, renal, and oncology areas. The company operates a specialized unit for Phase 2 clinical trials, known as the Ribocure Clinic, which is equipped wit... Read More
